Epidemiology, Treatment Patterns, Humanistic And Economic Burden Of Biliary Tract Carcinoma: A Systematic And Targeted Literature Review

Cost-Effectiveness Analysis of Pembrolizumab for First-Line Treatment in Patients with Persistent, Recurrent, and Metastatic Cervical Cancer in the United States: Results from the Final Analysis of Trial

Cost-Effectiveness of Pembrolizumab Plus Chemotherapy, with or without Bevacizumab for the First-Line Treatment of Pd-L1-Positive Patients with Persistent, Recurrent, or Metastatic Cervical Cancer in France
